Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PHA-543613
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
PHA-543613 is a potent and selective agonist for the α7 subtype of neural nicotinic acetylcholine receptors. It exhibits good oral bioavailability and brain penetration. The drug was initially developed for cognitive deficits in schizophrenia and has shown potential in improving memory in models of Alzheimer's disease and other neurodegenerative conditions.
- Other names
- PHA-543613EPHA543613EPHA 543613E
02
Targets
CHRNA7 (α7 nicotinic receptor)HTR3A (5-hydroxytryptamine receptor 3A)
Beyond the preview
Go deeper on PHA-543613.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PHA-543613.